A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

by | Apr 23, 2026 | Clinical Trials | 0 comments

​ Conditions: Early Breast Cancer

Interventions: Drug: Giredestrant

Sponsors: Genentech, Inc.

Not yet recruiting Conditions: Early Breast Cancer
Interventions: Drug: Giredestrant
Sponsors: Genentech, Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *